AAPL296.21+1.91 (+0.65%) ▲|ABBV234.04-0.72 (-0.31%) ▼|ABT90.83+0.30 (+0.33%) ▲|ACN129.72+2.71 (+2.13%) ▲|ADBE197.69+0.26 (+0.13%) ▲|AMAT576.95-8.93 (-1.52%) ▼|AMD508.73-11.12 (-2.14%) ▼|AMGN351.62+4.61 (+1.33%) ▲|AMT174.75-4.64 (-2.58%) ▼|AMZN239.36+5.25 (+2.24%) ▲|AVGO381.53+1.38 (+0.36%) ▲|AXP342.34+4.56 (+1.35%) ▲|BA220.46+3.75 (+1.73%) ▲|BAC57.54-0.37 (-0.64%) ▼|BKNG183.01+14.07 (+8.33%) ▲|BLK982.03-33.30 (-3.28%) ▼|BMY54.93-0.60 (-1.08%) ▼|BNY144.63-2.66 (-1.81%) ▼|BRK-B495.14+2.33 (+0.47%) ▲|C143.41-1.57 (-1.08%) ▼|CAT981.79-2.46 (-0.25%) ▼|CL92.63+1.20 (+1.31%) ▲|CMCSA22.53-0.28 (-1.21%) ▼|COF201.83+4.02 (+2.03%) ▲|COP107.25-2.72 (-2.47%) ▼|COST962.01+4.33 (+0.45%) ▲|CRM153.56+0.14 (+0.09%) ▲|CSCO120.03-1.13 (-0.93%) ▼|CVS100.69-0.89 (-0.87%) ▼|CVX171.98-4.00 (-2.27%) ▼|DE606.52+14.58 (+2.46%) ▲|DHR186.98+8.01 (+4.47%) ▲|DIS101.88-1.66 (-1.60%) ▼|DUK125.25+0.20 (+0.16%) ▲|EMR141.35-1.79 (-1.25%) ▼|FDX312.32-4.92 (-1.55%) ▼|GD345.39-4.95 (-1.41%) ▼|GE364.15+7.68 (+2.15%) ▲|GEV1,051.94+16.96 (+1.64%) ▲|GILD125.56+0.51 (+0.41%) ▲|GM79.60+0.65 (+0.82%) ▲|GOOG348.14+2.06 (+0.59%) ▲|GOOGL349.02+2.93 (+0.85%) ▲|GS1,076.69-17.75 (-1.62%) ▼|HD340.03+15.58 (+4.80%) ▲|HON227.05+4.68 (+2.10%) ▲|IBM261.43-3.51 (-1.32%) ▼|INTC130.54-1.74 (-1.32%) ▼|INTU266.61+8.56 (+3.32%) ▲|ISRG400.83-2.35 (-0.58%) ▼|JNJ239.86+0.78 (+0.33%) ▲|JPM332.22-1.92 (-0.57%) ▼|KO80.90+0.59 (+0.73%) ▲|LIN517.51+5.25 (+1.02%) ▲|LLY1,106.69-0.39 (-0.04%) ▼|LMT494.44-9.23 (-1.83%) ▼|LOW220.51+6.97 (+3.26%) ▲|LRCX363.24-8.09 (-2.18%) ▼|MA493.80+5.73 (+1.17%) ▲|MCD273.49+1.83 (+0.67%) ▲|MDLZ62.14+1.08 (+1.77%) ▲|MDT80.36-0.27 (-0.33%) ▼|META556.87-5.33 (-0.95%) ▼|MMM166.71+4.87 (+3.01%) ▲|MO71.70+0.09 (+0.12%) ▲|MRK120.76+1.16 (+0.97%) ▲|MS220.38-5.65 (-2.50%) ▼|MSFT371.05-2.89 (-0.77%) ▼|MU1,019.42-32.35 (-3.08%) ▼|NEE86.80+0.37 (+0.42%) ▲|NFLX71.87-0.95 (-1.30%) ▼|NKE42.00-0.39 (-0.91%) ▼|NOW93.61-2.34 (-2.43%) ▼|NVDA198.20-1.80 (-0.90%) ▼|ORCL155.86-9.31 (-5.63%) ▼|PEP142.47+0.42 (+0.30%) ▲|PFE24.04-0.68 (-2.77%) ▼|PG152.51+1.65 (+1.09%) ▲|PLTR112.97-3.74 (-3.20%) ▼|PM177.53-1.16 (-0.65%) ▼|QCOM194.61-9.52 (-4.66%) ▼|RTX185.28-1.12 (-0.60%) ▼|SBUX103.31+2.26 (+2.24%) ▲|SCHW91.58-1.59 (-1.71%) ▼|SO94.84-0.10 (-0.10%) ▼|SPG219.79+3.05 (+1.41%) ▲|T22.40-0.42 (-1.82%) ▼|TMO487.12+17.77 (+3.79%) ▲|TMUS182.82-1.76 (-0.95%) ▼|TSLA375.87-5.74 (-1.50%) ▼|TXN301.87-2.49 (-0.82%) ▼|UBER73.70+4.03 (+5.78%) ▲|UNH403.68-5.57 (-1.36%) ▼|UNP259.37+0.76 (+0.29%) ▲|UPS104.86-0.98 (-0.92%) ▼|USB59.98-0.08 (-0.12%) ▼|V331.06+2.58 (+0.78%) ▲|VZ45.52-1.21 (-2.59%) ▼|WFC83.84-0.30 (-0.35%) ▼|WMT119.56+0.14 (+0.12%) ▲|XOM136.21-3.52 (-2.52%) ▼|AAPL296.21+1.91 (+0.65%) ▲|ABBV234.04-0.72 (-0.31%) ▼|ABT90.83+0.30 (+0.33%) ▲|ACN129.72+2.71 (+2.13%) ▲|ADBE197.69+0.26 (+0.13%) ▲|AMAT576.95-8.93 (-1.52%) ▼|AMD508.73-11.12 (-2.14%) ▼|AMGN351.62+4.61 (+1.33%) ▲|AMT174.75-4.64 (-2.58%) ▼|AMZN239.36+5.25 (+2.24%) ▲|AVGO381.53+1.38 (+0.36%) ▲|AXP342.34+4.56 (+1.35%) ▲|BA220.46+3.75 (+1.73%) ▲|BAC57.54-0.37 (-0.64%) ▼|BKNG183.01+14.07 (+8.33%) ▲|BLK982.03-33.30 (-3.28%) ▼|BMY54.93-0.60 (-1.08%) ▼|BNY144.63-2.66 (-1.81%) ▼|BRK-B495.14+2.33 (+0.47%) ▲|C143.41-1.57 (-1.08%) ▼|CAT981.79-2.46 (-0.25%) ▼|CL92.63+1.20 (+1.31%) ▲|CMCSA22.53-0.28 (-1.21%) ▼|COF201.83+4.02 (+2.03%) ▲|COP107.25-2.72 (-2.47%) ▼|COST962.01+4.33 (+0.45%) ▲|CRM153.56+0.14 (+0.09%) ▲|CSCO120.03-1.13 (-0.93%) ▼|CVS100.69-0.89 (-0.87%) ▼|CVX171.98-4.00 (-2.27%) ▼|DE606.52+14.58 (+2.46%) ▲|DHR186.98+8.01 (+4.47%) ▲|DIS101.88-1.66 (-1.60%) ▼|DUK125.25+0.20 (+0.16%) ▲|EMR141.35-1.79 (-1.25%) ▼|FDX312.32-4.92 (-1.55%) ▼|GD345.39-4.95 (-1.41%) ▼|GE364.15+7.68 (+2.15%) ▲|GEV1,051.94+16.96 (+1.64%) ▲|GILD125.56+0.51 (+0.41%) ▲|GM79.60+0.65 (+0.82%) ▲|GOOG348.14+2.06 (+0.59%) ▲|GOOGL349.02+2.93 (+0.85%) ▲|GS1,076.69-17.75 (-1.62%) ▼|HD340.03+15.58 (+4.80%) ▲|HON227.05+4.68 (+2.10%) ▲|IBM261.43-3.51 (-1.32%) ▼|INTC130.54-1.74 (-1.32%) ▼|INTU266.61+8.56 (+3.32%) ▲|ISRG400.83-2.35 (-0.58%) ▼|JNJ239.86+0.78 (+0.33%) ▲|JPM332.22-1.92 (-0.57%) ▼|KO80.90+0.59 (+0.73%) ▲|LIN517.51+5.25 (+1.02%) ▲|LLY1,106.69-0.39 (-0.04%) ▼|LMT494.44-9.23 (-1.83%) ▼|LOW220.51+6.97 (+3.26%) ▲|LRCX363.24-8.09 (-2.18%) ▼|MA493.80+5.73 (+1.17%) ▲|MCD273.49+1.83 (+0.67%) ▲|MDLZ62.14+1.08 (+1.77%) ▲|MDT80.36-0.27 (-0.33%) ▼|META556.87-5.33 (-0.95%) ▼|MMM166.71+4.87 (+3.01%) ▲|MO71.70+0.09 (+0.12%) ▲|MRK120.76+1.16 (+0.97%) ▲|MS220.38-5.65 (-2.50%) ▼|MSFT371.05-2.89 (-0.77%) ▼|MU1,019.42-32.35 (-3.08%) ▼|NEE86.80+0.37 (+0.42%) ▲|NFLX71.87-0.95 (-1.30%) ▼|NKE42.00-0.39 (-0.91%) ▼|NOW93.61-2.34 (-2.43%) ▼|NVDA198.20-1.80 (-0.90%) ▼|ORCL155.86-9.31 (-5.63%) ▼|PEP142.47+0.42 (+0.30%) ▲|PFE24.04-0.68 (-2.77%) ▼|PG152.51+1.65 (+1.09%) ▲|PLTR112.97-3.74 (-3.20%) ▼|PM177.53-1.16 (-0.65%) ▼|QCOM194.61-9.52 (-4.66%) ▼|RTX185.28-1.12 (-0.60%) ▼|SBUX103.31+2.26 (+2.24%) ▲|SCHW91.58-1.59 (-1.71%) ▼|SO94.84-0.10 (-0.10%) ▼|SPG219.79+3.05 (+1.41%) ▲|T22.40-0.42 (-1.82%) ▼|TMO487.12+17.77 (+3.79%) ▲|TMUS182.82-1.76 (-0.95%) ▼|TSLA375.87-5.74 (-1.50%) ▼|TXN301.87-2.49 (-0.82%) ▼|UBER73.70+4.03 (+5.78%) ▲|UNH403.68-5.57 (-1.36%) ▼|UNP259.37+0.76 (+0.29%) ▲|UPS104.86-0.98 (-0.92%) ▼|USB59.98-0.08 (-0.12%) ▼|V331.06+2.58 (+0.78%) ▲|VZ45.52-1.21 (-2.59%) ▼|WFC83.84-0.30 (-0.35%) ▼|WMT119.56+0.14 (+0.12%) ▲|XOM136.21-3.52 (-2.52%) ▼|
27.5 C
New York
Wednesday, June 24, 2026

Tag: evaluation

newssourceFORcompanyinformationcontent1marketreleases

RayStation used for pioneering clinical milestone at Helsinki University Hospital – first treatment with accelerator-based BNCT in Europe

STOCKHOLM, June 16, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that RayStation®*, its advanced treatment planning system, was used in...

Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC

SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Xinhua Silk Road: 3rd Tianjin International Shipping Industry Expo kicks off to boost win-win cooperation

BEIJING, June 14, 2025 /PRNewswire/ -- The third Tianjin International Shipping Industry Expo (TISIE) kicked off in north China's Tianjin Municipality on Thursday, attracting the...

Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego

- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten...

Trusted Crypto Casinos Are Taking Over Online Gambling in 2025: Exclusive Report By Radcred

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 
Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips.

Baltimore Expands Use of Evolve™ Rodent Birth Control Following Successful Pilot

Full Scale Implementation Expected SURPRISE, Ariz., June 13, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a leader in fertility control solutions...

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib 
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

Cancer Pain Market Set to Transform by 2034 Due to Launch of Breakthrough Therapies | DelveInsight

According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease...

China Construction Bank Establishes CCB SG Vision Foundation with TT Foundation Advisors

CCB becomes the first Chinese financial institution in Singapore to collaborate with TT Foundation Advisors on philanthropyThe Foundation has made its first contribution to...

Standard Industries Announces Molecule.one as Winner of $1 Million AI Challenge

Novel AI Application to Accelerate the Development and Production of Pharmaceuticals NEW YORK, June 12, 2025 /PRNewswire/ -- Standard Industries ("Standard"), a privately-held global industrial...

Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEvaluation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers